Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-TCR055 in Unresectable Hepatocellular Carcinoma
NCT03971747Phase 1Unknown
- Sponsor
- AbelZeta
- Start
- Aug 2019
- Primary completion
- Jun 2020
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AFP specific T cell receptor T cells in hepatocellular carcinoma (HCC), sponsored by AbelZeta. Primary endpoint: Incidence of treatment related adverse events as assessed by CTCAE v4.0 at 12 months. Status: unknown.
02
Drugs
AFP specific T cell receptor T cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03971747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03971747.